Modifications of human carboxylesterase for improved prodrug activation

Bibliography

• Potter PM, Wadkins RM. Carboxylesterases – detoxifying enzymes and targets for drug therapy. Curr Med Chem 2006;13:1045-54
   PubMed Web of Science ®Google Scholar
• Redinbo MR, Potter PM. Mammalian carboxylesterases: from drug targets to protein therapeutics. Drug Discov Today 2005;10:313-25
   PubMed Web of Science ®Google Scholar
• Satoh T, Hosokawa M. The mammalian carboxylesterases: from molecules to function. Ann Rev Pharmacol Toxicol 1998;38:257-88
   PubMed Web of Science ®Google Scholar
• Cashman J, Perroti B, Berkman C, et al. Pharmacokinetics and molecular detoxification. Environ Health Perspect 1996;104:23-40
   PubMed Web of Science ®Google Scholar
• Li B, Sedlacek M, Manoharan I, et al. Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. Biochem Pharmacol 2005;70:1673-84
   PubMed Web of Science ®Google Scholar
• Morton CL, Iacono L, Hyatt JL, et al. Metabolism and antitumor activity of CPT-11 in plasma esterase-deficient mice. Cancer Chemother Pharmacol 2005;56:629-36
   PubMed Web of Science ®Google Scholar
• Morton CL, Taylor KR, Iacono L, et al. Metabolism of CPT-11 in esterase deficient mice. Proc Am Assoc Cancer Res 2002;43:248
   Google Scholar
• Morton CL, Wierdl M, Oliver L, et al. Activation of CPT-11 in mice: identification and analysis of a highly effective plasma esterase. Cancer Res 2000;60:4206-10
   PubMed Web of Science ®Google Scholar
• Pindel EV, Kedishvili NY, Abraham TL, et al. Purification and cloning of a broad substrate specificity human liver carboxylesterase that catalyzes the hydrolysis of cocaine and heroin. J Biol Chem 1997;272:14769-75
   PubMed Web of Science ®Google Scholar
• Kamendulis LM, Brzezinski MR, Pindel EV, et al. Metabolism of cocaine and heroin is catalyzed by the same human liver carboxylesterases. J Pharmacol Exp Ther 1996;279:713-7
   PubMed Web of Science ®Google Scholar
• Brzezinski MR, Abraham TL, Stone CL, et al. Purification and characterization of a human liver cocaine carboxylesterase that catalyzes the production of benzoylecgonine and the formation of cocaethylene from alcohol and cocaine. Biochem Pharmacol 1994;48:1747-55
   PubMed Web of Science ®Google Scholar
• Brzezinski MR, Spink BJ, Dean RA, et al. Human liver carboxylesterase hCE-1: binding specificity for cocaine, heroin, and their metabolites and analogs. Drug Metab Dispos 1997;25:1089-96
   PubMed Web of Science ®Google Scholar
• Danks MK, Morton CL, Krull EJ, et al. Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy. Clin Cancer Res 1999;5:917-24
   PubMed Web of Science ®Google Scholar
• Humerickhouse R, Lohrbach K, Li L, et al. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res 2000;60:1189-92
   PubMed Web of Science ®Google Scholar
• Khanna R, Morton CL, Danks MK, et al. Proficient metabolism of CPT-11 by a human intestinal carboxylesterase. Cancer Res 2000;60:4725-8
   PubMed Web of Science ®Google Scholar
• Quinney SK, Sanghani SP, Davis WI, et al. Hydrolysis of capecitabine to 5′-deoxy-5-fluorocytidine by human carboxylesterases and inhibition by loperamide. J Pharmacol Exp Ther 2005;313:1011-6
   PubMed Web of Science ®Google Scholar
• Crow JA, Borazjani A, Potter PM, et al. Hydrolysis of pyrethroids by human and rat tissues: examination of intestinal, liver and serum carboxylesterases. Toxicol Appl Pharmacol 2007;221:1-12
   PubMed Web of Science ®Google Scholar
• Ross MK, Borazjani A, Edwards CC, et al. Hydrolytic metabolism of pyrethroids by human and other mammalian carboxylesterases. Biochem Pharmacol 2006;71:657-69
   PubMed Web of Science ®Google Scholar
• Ross MK, Potter PM, Borazjani A. Hydrolytic metabolism of pyrethroids by human carboxylesterases and rodent and human liver microsomes. Tox Sci 2005;84(S1):A1569
   Google Scholar
• Zhang J, Burnell JC, Dumaual N, et al. Binding and hydrolysis of meperidine by human liver carboxylesterase hCE-1. J Pharmacol Exp Ther 1999;290:314-8
   PubMed Web of Science ®Google Scholar
• Sun Z, Murry DJ, Sanghani SP, et al. Methylphenidate is stereoselectively hydrolyzed by human carboxylesterase CES1A1. J Pharmacol Exp Ther 2004;310:469-76
   PubMed Web of Science ®Google Scholar
• Takai S, Matsuda A, Usami Y, et al. Hydrolytic profile for ester- or amide-linkage by carboxylesterases pI 5.3 and 4.5 from human liver. Biol Pharm Bull 1997;20:869-73
   PubMed Web of Science ®Google Scholar
• Shi D, Yang J, Yang D, et al. Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel. J Pharmacol Exp Ther 2006;319:1477-84
   PubMed Web of Science ®Google Scholar
• Tang M, Mukundan M, Yang J, et al. Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol. J Pharmacol Exp Ther 2006;319:1467-76
   PubMed Web of Science ®Google Scholar
• Bencharit S, Morton CL, Howard-Williams EL, et al. Structural insights into CPT-11 activation by mammalian carboxylesterases. Nat Struct Biol 2002;9:337-42
   PubMedGoogle Scholar
• Bencharit S, Morton CL, Hyatt JL, et al. Crystal structure of human carboxylesterase 1 complexed with the Alzheimer's drug tacrine. From binding promiscuity to selective inhibition. Chem Biol 2003;10:341-9
   PubMed Web of Science ®Google Scholar
• Bencharit S, Morton CL, Xue Y, et al. Structural basis of heroin and cocaine metabolism by a promiscuous human drug-processing enzyme. Nat Struct Biol 2003;10:349-56
   PubMedGoogle Scholar
• Gillilan R. Acetylcholinesterase molecular dynamics. Available from: http://opendx.sdsc.edu/animations/chemistry/chem-ctc.mpg
   Google Scholar
• Potter PM, Pawlik CA, Morton CL, et al. Isolation and partial characterization of a cDNA encoding a rabbit liver carboxylesterase that activates the prodrug Irinotecan (CPT-11). Cancer Res 1998;52:2646-51
   Google Scholar
• Wadkins RM, Morton CL, Weeks JK, et al. Structural constraints affect the metabolism of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) by carboxylesterases. Mol Pharmacol 2001;60:355-62
   PubMed Web of Science ®Google Scholar
• Schwer H, Langmann T, Daig R, et al. Molecular cloning and characterization of a novel putative carboxylesterase, present in human intestine and liver. Biochem Biophys Res Commun 1997;233:117-20
   PubMed Web of Science ®Google Scholar
• Sanghani SP, Quinney SK, Fredenburg TB, et al. Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3. Drug Metab Dispos 2004;32:505-11
   PubMed Web of Science ®Google Scholar
• Hosokawa M. Structure and catalytic properties of carboxylesterase isozymes involved in metabolic activation of prodrugs. Molecules 2008;13:412-31
   PubMed Web of Science ®Google Scholar
• Morton CL, Potter PM. Comparison of Escherichia coli, Saccharomyces cerevisiae, Pichia pastoris, Spodoptera frugiperda and COS7 cells for recombinant gene expression: application to a rabbit liver carboxylesterase. Mol Biotechnol 2000;16:193-202
   PubMed Web of Science ®Google Scholar
• Danks MK, Potter PM. Enzyme-prodrug systems: carboxylesterase/CPT-11. Methods Mol Med 2004;90:247-62
   PubMedGoogle Scholar
• Potter PM, Danks MK. Carboxylesterase-mediated activation of irinotecan. Cancer Res Alert 2000;2:80-3
   Google Scholar
• Senter PD, Springer CJ. Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates. Adv Drug Deliv Rev 2001;53:247-64
   PubMed Web of Science ®Google Scholar
• Senter PD, Beam KS, Mixan B, et al. Identification and activities of human carboxylesterases for the activation of CPT-11, a clinically approved anticancer drug. Bioconjug Chem 2001;12:1074-80
   PubMed Web of Science ®Google Scholar
• Senter PD. Activation of prodrugs by antibody-enzyme conjugates: a new approach to cancer therapy. FASEB J 1990;4:188-93
   PubMed Web of Science ®Google Scholar
• Senter PD. Antitumor effects of antibody enzyme conjugates in combination with prodrugs. Front Radiat Ther Oncol 1990;24:132-41; discussion 161-165
   PubMedGoogle Scholar
• Meck M, Wierdl M, Wagner L, et al. A VDEPT approach to purging neuroblastoma cells from hematopoeitic cells using adenovirus encoding rabbit carboxylesterase and CPT-11. Cancer Res 2001;61:5083-9
   PubMed Web of Science ®Google Scholar
• Wagner LM, Guichard SM, Burger RA, et al. Efficacy and toxicity of a virus-directed enzyme prodrug therapy purging method: preclinical assessment and application to bone marrow samples from neuroblastoma patients. Cancer Res 2002;62:5001-7
   PubMed Web of Science ®Google Scholar
• Wierdl M, Morton CL, Weeks JK, et al. Sensitization of human tumor cells to CPT-11 via adenoviral-mediated delivery of a rabbit liver carboxylesterase. Cancer Res 2001;61:5078-82
   PubMed Web of Science ®Google Scholar
• Oosterhoff D, Overmeer RM, de Graaf M, et al. Adenoviral vector-mediated expression of a gene encoding secreted, EpCAM-targeted carboxylesterase-2 sensitises colon cancer spheroids to CPT-11. Br J Cancer 2005;92:882-7
   PubMed Web of Science ®Google Scholar
• Oosterhoff D, Pinedo HM, van der Meulen IH, et al. Secreted and tumour targeted human carboxylesterase for activation of irinotecan. Br J Cancer 2002;87:659-64
   PubMed Web of Science ®Google Scholar
• Oosterhoff D, Pinedo HM, Witlox MA, et al. Gene-directed enzyme prodrug therapy with carboxylesterase enhances the anticancer efficacy of the conditionally replicating adenovirus AdDelta24. Gene Ther 2005;12:1011-8
   PubMed Web of Science ®Google Scholar
• Oosterhoff D, Witlox MA, van Beusechem VW, et al. Gene-directed enzyme prodrug therapy for osteosarcoma: sensitization to CPT-11 in vitro and in vivo by adenoviral delivery of a gene encoding secreted carboxylesterase-2. Mol Cancer Ther 2003;2:765-71
   PubMed Web of Science ®Google Scholar
• Wierdl M, Tsurkan L, Hyatt JL, et al. An improved human carboxylesterase for use in enzyme/prodrug therapy with CPT-11. Cancer Gene Ther 2008;15:183-92
   PubMed Web of Science ®Google Scholar
• Yoon KJ, Qi J, Remack JS, et al. An etoposide prodrug for development of a dual prodrug-enzyme approach to antitumor therapy. Mol Cancer Ther 2006;5:1577-84
   PubMed Web of Science ®Google Scholar
• Yoon KJ, Potter PM, Danks MK. Development of prodrugs for enzyme-mediated, tumor-selective therapy. Curr Med Chem Anticancer Agents 2005;5:107-13
   PubMedGoogle Scholar
• Lange B, Schroeder U, Huebener N, et al. Rationally designed hydrolytically activated etoposide prodrugs, a novel strategy for the treatment of neuroblastoma. Cancer Lett 2003;197:225-30
   PubMed Web of Science ®Google Scholar
• Jikai J, Shamis M, Huebener N, et al. Neuroblastoma directed therapy by a rational prodrug design of etoposide as a substrate for tyrosine hydroxylase. Cancer Lett 2003;197:219-24
   PubMed Web of Science ®Google Scholar
• Schroeder U, Bernt KM, Lange B, et al. Hydrolytically activated etoposide prodrugs inhibit MDR-1 function and eradicate established MDR-1 multidrug-resistant T-cell leukemia. Blood 2003;102:246-53
   PubMed Web of Science ®Google Scholar
• Wrasidlo W, Schroder U, Bernt K, et al. Synthesis, hydrolytic activation and cytotoxicity of etoposide prodrugs. Bioorg Med Chem Lett 2002;12:557-60
   PubMed Web of Science ®Google Scholar
• Meresse P, Dechaux E, Monneret C, et al. Etoposide: discovery and medicinal chemistry. Curr Med Chem 2004;11:2443-66
   PubMed Web of Science ®Google Scholar
• Senter PD, Marquardt H, Thomas BA, et al. The role of rat serum carboxylesterase in the activation of paclitaxel and camptothecin prodrugs. Cancer Res 1996;56:1471-74
   PubMed Web of Science ®Google Scholar
• Wrasidlo W, Gaedicke G, Guy RK, et al. A novel 2′-(N-methylpyridinium acetate) prodrug of paclitaxel induceds superior antitumor responses in preclinical cancer models. Bioconjug Chem 2002;13:1093-99
   PubMed Web of Science ®Google Scholar
• Bhat L, Liu Y, Victory SF, et al. Synthesis and evaluation of paclitaxel C7 derivatives: solution phase synthesis of combinatorial libraries. Bioorg Med Chem Lett 1998;8:3181-6
   PubMed Web of Science ®Google Scholar
• Boge TC, Wu ZJ, Himes RH, et al. Conformationally restricted paclitaxel analogues: macrocyclic mimics of the “hydrophobic collapse” conformation. Bioorg Med Chem Lett 1999;9:3047-52
   PubMed Web of Science ®Google Scholar
• Liu Y, Ali SM, Boge TC, et al. A systematic SAR study of C10 modified paclitaxel analogues using a combinatorial approach. Comb Chem High Throughput Screen 2002;5:39-48
   PubMed Web of Science ®Google Scholar
• Niethammer A, Gaedicke G, Lode HN, et al. Synthesis and preclinical characterization of a paclitaxel prodrug with improved antitumor activity and water solubility. Bioconjug Chem 2001;12:414-20
   PubMed Web of Science ®Google Scholar
• Seligson AL, Terry RC, Bressi JC, et al. A new prodrug of paclitaxel: synthesis of protaxel. Anticancer Drugs 2001;12:305-13
   PubMed Web of Science ®Google Scholar
• Barthel BL, Torres RC, Hyatt JL, et al. Identification of human intestinal carboxylesterase as the primary enzyme for activation of a doxazolidine carbamate prodrug. J Med Chem 2008;51:298-304
   PubMed Web of Science ®Google Scholar
• Ravel D, Dubois V, Quinonero J, et al. Preclinical toxicity, toxicokinetics, and antitumoral efficacy studies of DTS-201, a tumor-selective peptidic prodrug of doxorubicin. Clin Cancer Res 2008;14:1258-65
   PubMed Web of Science ®Google Scholar
• Cherif A, Farquhar D. N-(5,5-diacetoxypent-1-yl)doxorubicin: a new intensely potent doxorubicin analogue. J Med Chem 1992;35:3208-14
   PubMed Web of Science ®Google Scholar
• Farquhar D, Newman RA, Zuckerman JE, et al. Doxorubicin analogues incorporating chemically reactive substituents. J Med Chem 1991;34:561-4
   PubMed Web of Science ®Google Scholar
• Zwelling LA, Altschuler E, Cherif A, et al. N-(5,5-diacetoxypentyl)doxorubicin: a novel anthracycline producing DNA interstrand cross-linking and rapid endonucleolytic cleavage in human leukemia cells. Cancer Res 1991;51:6704-07
   PubMed Web of Science ®Google Scholar
• Farquhar D, Cherif A, Bakina E, et al. Intensely potent doxorubicin analogues: structure-activity relationship. J Med Chem 1998;41:965-72
   PubMed Web of Science ®Google Scholar
• Munger JS, Shi GP, Mark EA, et al. A serine esterase released by human alveolar macrophages is closely related to liver microsomal carboxylesterases. J Biol Chem 1991;266:18832-8
   PubMed Web of Science ®Google Scholar
• Leamon CP, Reddy JA, Vlahov IR, et al. Synthesis and biological evaluation of EC140: a novel folate-targeted vinca alkaloid conjugate. Bioconjug Chem 2006;17:1226-32
   PubMed Web of Science ®Google Scholar
• Leamon CP, Reddy JA, Vlahov IR, et al. Synthesis and biological evaluation of EC72: a new folate-targeted chemotherapeutic. Bioconjug Chem 2005;16:803-11
   PubMed Web of Science ®Google Scholar
• Leamon CP, Reddy JA, Vlahov IR, et al. Preclinical antitumor activity of a novel folate-targeted dual drug conjugate. Mol Pharm 2007;4:659-67
   PubMed Web of Science ®Google Scholar
• Reddy JA, Dorton R, Westrick E, et al. Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate. Cancer Res 2007;67:4434-42
   PubMed Web of Science ®Google Scholar
• Reddy JA, Westrick E, Santhapuram HK, et al. Folate receptor-specific antitumor activity of EC131, a folate-maytansinoid conjugate. Cancer Res 2007;67:6376-82
   PubMed Web of Science ®Google Scholar
• Kunimoto T, Nitta K, Tanaka T, et al. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 1987;47:5944-7
   PubMed Web of Science ®Google Scholar
• Tsuji T, Kaneda N, Kado K, et al. CPT-11 converting enzyme from rat serum: purification and some properties. J Pharmacobiodyn 1991;14:341-9
   PubMedGoogle Scholar
• Pancook JD, Pecht G, D'Arigo K, et al. Optimization of butyrylcholinesterase for the targeted activation of CPT-11. Proc Am Assoc Cancer Res 2004;45:2198
   Google Scholar
• Simon M, Argiris A, Murren JR. Progress in the therapy of small cell lung cancer. Crit Rev Oncol Hematol 2004;49:119-33
   PubMed Web of Science ®Google Scholar
• Langer CJ. The global role of irinotecan in the treatment of lung cancer: 2003 update. Oncology 2003;17:30-40
   PubMedGoogle Scholar
• Furman WL, Stewart CF, Poquette CA, et al. Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol 1999;17:1815-24
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Rothenberg ML, Pitot HC, et al. Irinotecan (CPT-11) therapy for patients with previously treated metastatic colorectal cancer (CRC): overall results of FDA-reviewed pivotal US clinical trials (Meeting abstract). Proc Ann Meet Am Soc Clin Oncol 1997;16:A803
   Google Scholar
• Kurita A, Kado S, Kaneda N, et al. Modified irinotecan hydrochloride CPT-11) administration schedule improves induction of delayed-onset diarrhea in rats. Cancer Chemother Pharmacol 2000;46:211-20
   PubMed Web of Science ®Google Scholar
• Ikegami T, Ha L, Arimori K, et al. Intestinal alkalization as a possible preventive mechanism in irinotecan (CPT-11)-induced diarrhea. Cancer Res 2002;62:179-87
   PubMed Web of Science ®Google Scholar
• Takeda Y, Kobayashi K, Akiyama Y, et al. Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients. Int J Cancer 2001;92:269-75
   PubMed Web of Science ®Google Scholar
• Saliba F, Hagipantelli R, Misset JL, et al. Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment. J Clin Oncol 1998;16:2745-51
   PubMed Web of Science ®Google Scholar
• Green NK, Youngs DJ, Neoptolemos JP, et al. Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene. Cancer Gene Ther 1997;4:229-38
   PubMed Web of Science ®Google Scholar
• Trinh QT, Austin EA, Murray DM, et al. Enzyme/prodrug gene therapy: comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line. Cancer Res 1995;55:4808-12
   PubMed Web of Science ®Google Scholar
• Fillat C, CarrióM, Cascante A, et al. Suicide gene therapy mediated by the Herpes simplex virus thymidine kinase gene/ganciclovir system: fifteen years of application. Curr Gene Ther 2003;3:13-26
   PubMedGoogle Scholar
• Grove JI, Searle PF, Weedon SJ, et al. Virus-directed enzyme prodrug therapy using CB1954. Anticancer Drug Des 1999;14:461-72
   PubMedGoogle Scholar
• Searle PF, Weedon SJ, McNeish IA, et al. Sensitisation of human ovarian cancer cells to killing by the prodrug CB1954 following retroviral or adenoviral transfer of the E. coli nitroreductase gene. Adv Exp Med Biol 1998;451:107-13
   PubMed Web of Science ®Google Scholar
• Bridgewater JA, Knox RJ, Pitts JD, et al. The bystander effect of the nitroreductase/CB1954 enzyme/prodrug system is due to a cell-permeable metabolite. Hum Gene Ther 1997;8:709-17
   PubMed Web of Science ®Google Scholar
• Bailey SM, Hart IR. Nitroreductase activation of CB1954–an alternative ‘suicide’ gene system. Gene Ther 1997;4:80-1
   PubMed Web of Science ®Google Scholar
• Bailey SM, Knox RJ, Hobbs SM, et al. Investigation of alternative prodrugs for use with E. coli nitroreductase in ‘suicide gene’ approaches to cancer therapy. Gene Ther 1996;3:1143-50
   PubMed Web of Science ®Google Scholar
• Garcia-Sanchez F, Pizzorno G, Fu SQ, et al. Cytosine deaminase adenoviral vector and 5-fluorocytosine selectively reduce breast cancer cells 1 million-fold when they contaminate hematopoietic cells: a potential purging method for autologous transplantation. Blood 1998;92:672-82
   PubMed Web of Science ®Google Scholar
• Hanna NN, Mauceri HJ, Wayne JD, et al. Virally directed cytosine deaminase/5-fluorocytosine gene therapy enhances radiation response in human cancer xenografts. Cancer Res 1997;57:4205-9
   PubMed Web of Science ®Google Scholar
• Bouali-Benazzouz R, Laine M, Vicat JM, et al. Therapeutic efficacy of the thymidine kinase/ganciclovir system on large experimental gliomas: a nuclear magnetic resonance imaging study. Gene Ther 1999;6:1030-7
   PubMed Web of Science ®Google Scholar
• Hwang HC, Smythe WR, Elshami AA, et al. Gene therapy using adenovirus carrying the herpes simplex-thymidine kinase gene to treat in vivo models of human malignant mesothelioma and lung cancer. Am J Respir Cell Mol Biol 1995;13:7-16
   PubMed Web of Science ®Google Scholar
• Vile RG, Nelson JA, Castleden S, et al. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res 1994;54:6228-34
   PubMed Web of Science ®Google Scholar
• Rill D, Santana V, Roberts W, et al. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 1994;84:380-3
   PubMed Web of Science ®Google Scholar
• Aboody KS, Brown A, Rainov NG, et al. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci USA 2000;97:12846-51
   PubMed Web of Science ®Google Scholar
• Aboody KS, Bush RA, Garcia E, et al. Development of a tumor-selective approach to treat metastatic cancer. PLoS One 2006;1:1-10
   Google Scholar
• Aboody KS, Najbauer J, Schmidt NO, et al. Targeting of melanoma brain metastases using engineered neural stem/progenitor cells. Neuro Oncol 2006;8:119-26
   PubMed Web of Science ®Google Scholar
• Aboody KS, Najbauer J, Danks MK. Stem and progenitor cell-mediated tumor selective gene therapy. Gene Ther 2008;15:739-52
   PubMed Web of Science ®Google Scholar
• Danks MK, Yoon KJ, Bush RA, et al. Tumor-targeted enzyme/prodrug therapy mediates long-term disease-free survival of mice bearing disseminated neuroblastoma. Cancer Res 2007;67:22-5
   PubMed Web of Science ®Google Scholar